Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update
Journal of Clinical Oncology · 10.11.2026
DOI: 10.1200/jco-26-02648 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Oncology, online erschienen am 10.11.2026. Verfasst von Yu-Pei Chen und 25 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Cli….
Abstract (Originalsprache)
PURPOSE To update the 2021 CSCO-ASCO guideline on chemotherapy in combination with radiotherapy for the definitive treatment of non-metastatic nasopharyngeal carcinoma (NPC), incorporating new evidence on radiotherapy techniques and target-volume de-escalation, chemotherapy regimens and their sequencing, adjuvant therapy, and immunotherapy for patients with stage IB-III disease. METHODS A multidisciplinary Expert Panel reviewed evidence published since the prior guideline, including randomized controlled trials, systematic reviews, meta-analyses, and relevant prospective and retrospective studies. Outcomes of interest included overall survival, failure-free or progression-free survival, locoregional and distant disease control, acute and late toxicities, and patient-reported quality of life. Recommendations were developed using the ASCO guideline development process and Expert Panel consensus. RESULTS The updated evidence supports: IMRT with image guidance and MRI-based target delineation as core components of definitive treatment; selected response-adapted target delineation following induction chemotherapy; elective nodal de-escalation in appropriately selected patients; risk-adapted chemotherapy sequencing according to stage and biologic risk; cisplatin-based concurrent chemoradiotherapy; gemcitabine–cisplatin (GP) or docetaxel–cisplatin–fluorouracil (TPF) as preferred induction regimens; and selected adjuvant chemotherapy options, including metronomic capecitabine for patients with higher residual post-chemoradiotherapy risk. Several randomized trials evaluating PD-1 inhibitors have demonstrated improved disease-control outcomes, but overall survival data remain immature. RECOMMENDATIONS This guideline update provides recommendations on radiotherapy technique, dose, imaging, and target delineation; sequencing of additional chemotherapy with radiotherapy; concurrent chemotherapy options; induction chemotherapy regimens and timing; adjuvant chemotherapy options; and the role of immunotherapy. At present, the Panel makes no recommendation for or against routine addition of immunotherapy to induction-concurrent chemoradiotherapy; applicability of the trial evidence, benefits and harms, local approval and access, and patient preferences should guide individualized decisions. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center…
- American Society of Clinical Oncology, Alexandria, VA, USA.
- Princess Margaret Cancer Centre/University of Toronto, Toronto, ON, Canada.
- State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, P…
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Stanford University School of Medicine, Stanford, CA, USA.
ORCID-Profile: Yu-Pei Chen, Nofisat Ismaila, Shao Hui Huang, Wei Jiang, Brigette Ma, Quynh-Thu Le, A Dimitrios Colevas, Kevin Harrington, Sue S Yom, Brian O'Sullivan, Anthony T C Chan, Nancy Lee, Anne W M Lee, Jun-Lin Yi, Chao-Su Hu, Kun-Yu Yang, Qin Lin, Jin-Ching Lin, Melvin L K Chua, Ying Sun
Zitieren
APA
Chen, Y. P., Ismaila, N., Huang, S. H., Jiang, W., Ma, B., Haddad, R., Le, Q. T., Colevas, A. D., Harrington, K., Yom, S. S., O'Sullivan, B., Chan, A. T. C., Chan, A., Lee, N., Lee, A. W. M., Yi, J. L., Hu, C. S., Yang, K. Y., Lin, Q., …, & Sun, Y. (2026). Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-02648
Vancouver
Chen YP, Ismaila N, Huang SH, Jiang W, Ma B, Haddad R, et al. Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-02648
BibTeX
@article{Chen2026,
author = {Chen, Yu-Pei and Ismaila, Nofisat and Huang, Shao Hui and Jiang, Wei and Ma, Brigette and Haddad, Robert and Le, Quynh-Thu and Colevas, A Dimitrios and Harrington, Kevin and Yom, Sue S and O'Sullivan, Brian and Chan, Anthony T C and Chan, Annie and Lee, Nancy and Lee, Anne W M and Yi, Jun-Lin and Hu, Chao-Su and Yang, Kun-Yu and Lin, Qin and Whitley, Alexander C and Lin, Jin-Ching and Lam, Shu Wing Jack and Siahaan, Yosephtri and Chua, Melvin L K and Ma, Jun and Sun, Ying},
title = {Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-02648}
}
EUVIMED